Taxane based regimen (TBR) is the first option in patients with metastatic prostate cancer. Taxanes inhibit mitosis by decreasing the depolymerization of β-tubulin.1,2 There are several studies showing improved overall survival (OS) with TBR while some patients may not respond to this treatment.